LOGIN  |  REGISTER
Amneal Pharmaceuticals

Elevance Health Releases Impact Report

July 08, 2024 | Last Trade: US$365.96 0.52 -0.14

INDIANAPOLIS / Jul 08, 2024 / Business Wire / Elevance Health released its annual Impact Report, highlighting its continued evolution from a traditional health insurance benefits company to a diversified healthcare services organization.

The report details significant achievements including the industry-leading Health Equity Accreditation Plus from the National Committee for Quality Assurance, support for Medicaid eligibility renewals, and growth of Carelon.

In Elevance Health’s ongoing efforts to make a meaningful and healthy impact on communities, its workforce, and the environment, the organization was again included in America’s top 50 most community-minded companies and JUST Capital’s JUST 100. Elevance Health is especially proud of its associates and their enthusiastic participation in connecting with members who are socially isolated or living with serious or terminal illness.

Emphasized throughout the Impact Report is Elevance Health’s progress on serving the unique needs of each health plan member, building capabilities to assess and address the key drivers of health, creating partnerships in communities to implement solutions to healthcare challenges, and using data-driven insights to simplify, connect and personalize healthcare.

Explore the full report

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB